Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease

BackgroundProgramed death-ligand 1 (PD-L1) is overexpressed on renal tubular and vascular epithelial cells in inflammatory kidney diseases as well as on aged kidney podocytes, contributing to chronic kidney disease (CKD) progression. The association of serum soluble programed death-ligand 1 (sPD-L1)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Medicine
Subjects:	PD-1 PD-L1 chronic kidney disease dialysis immune checkpoint inhibitor soluble PD-L1 (sPD-L1)
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1530804/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
by: Waqas Safir, et al.
Published: (2025-02-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression
by: Alvin H.K. Cheung, MBBS, PhD, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles
by: Paola A. Castagnino, et al.
Published: (2025-12-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
by: Manuel Weber, et al.
Published: (2019-03-01)

ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer
by: Chiba N, et al.
Published: (2025-01-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
by: Myrna Luna-Gutiérrez, et al.
Published: (2025-01-01)

Formin protein DAAM1 positively regulates PD-L1 expression via mediating the JAK1/STAT1 axis in pancreatic cancer
by: Rui Xu, et al.
Published: (2025-01-01)

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis
by: Hongbin Lu, et al.
Published: (2025-01-01)

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
by: Jingjing Chai, et al.
Published: (2025-02-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01)

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment
by: Yifu Shu, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma
by: Li-Jun Wei, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma
by: Chao-Yan Yao, et al.
Published: (2025-02-01)

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered
by: Pengfei Chen, et al.
Published: (2025-03-01)

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy
by: Yiming Xu, et al.
Published: (2025-01-01)

Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer
by: Xiaoyu Kang, et al.
Published: (2025-01-01)

DRG2 as a Biomarker to Enhance the Predictive Efficacy of PD-L1 Immunohistochemistry Assays
by: Muralidharan Mani, et al.
Published: (2024-12-01)

Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis
by: Minjing Zou, et al.
Published: (2025-02-01)

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
by: Yang Xia, et al.
Published: (2025-01-01)

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
by: Preston Ngo, et al.
Published: (2025-02-01)

Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity
by: Yujia Zhao, et al.
Published: (2025-02-01)

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer
by: Sung Uk Bae, et al.
Published: (2025-03-01)

Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity
by: Jinzhi Lai, et al.
Published: (2025-01-01)

Feasibility of Endobronchial Ultrasound Guided Miniforceps Biopsy for PD‐L1 Expression and Quantitative Tissue Analysis
by: Max T. Wayne, et al.
Published: (2025-01-01)